ERBB2 and breast cancer: The following three novel ADCs with different cytotoxic payloads have been recently approved: trastuzumab deruxtecan that targets HER2 for breast cancer, sacituzumab govitecan that targets Trop2 for breast cancer and enfortumab vedotin that targets Nectin4 for bladder cancer, all through systemic use [87].